Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

The MTA board has approved an approximately $2 billion tunnel boring contract, which will extend Q train service from 96th ...

From marching bands to free food to billboards promoting the competition, inside the wild campaigns to win your vote.

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. Click here to read why SLS stock ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2 study titled ‘A ...

Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Study Overview: Enlivex Therapeutics is conducting a Phase 2 ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.